ESSO Course on the Management of High Risk Patients for Breast Cancer. A Multidisciplinary Approach



Similar documents
ESSO Advanced Course on Oncoplastic Breast Surgery June 2016

2 nd ESSO Advanced Course on the Surgical and Medical Management of Melanoma

ESSO Course on Peritoneal Surface Malignancy

Enhanced Recovery after Surgery: Benefits, Challenges and Solutions for Implementation

FAMILIAL CANCER ESO, CNIO AND NRCO CONFERENCE ON May 2016 Madrid, Spain. Chairs: R. Eeles, UK W.D. Foulkes, CA M. Robledo, ES H.

BREAST CANCER IN YOUNG WOMEN. OCTOBER 9 th 2015 Aula Magna UNIVERSITÀ DELLA SVIZZERA ITALIANA Lugano

NOTTINGHAM UNIVERSITY HOSPITAL NHS TRUST NOTTINGHAM BREAST INSTITUTE BREAST AND OVARIAN FAMILY HISTORY GUIDELINES

GOLNIK 17/06/10 COURSE ON LUNG CANCER AND MESOTHELIOMA June 2010 Golnik, Slovenia. Chair: T. Cufer, SI - G.L. Ceresoli, IT

Villejuif, Paris, France

Office of Population Health Genomics

13 September London, UK

I wish you an inspiring and successful learning experience here in Saint Petersburg. Yours Sincerely, Rachel Clark CEO, EXCEMED

Breast cancer research and a changing treatment pathway

CLINICAL ONCOLOGY MASTERCLASS IN April 2015 São Paulo, Brazil. Chairs: Scientific Co-ordinators: ESO - LATIN-AMERICAN PROGRAMME

The Center for Cancer Care. Comprehensive and compassionate care

eso InSIDe TrACK COnferenCe CAnCer COnferenCe 5-6 June 2014 Madrid, Spain Chairs: j. Benítez, es R. eeles, uk H. Vasen, nl

ESO INSIDE TRACK CONFERENCE. 4 th FAMILIAL CANCER CONFERENCE. 7-8 June 2010 Madrid, Spain. Chair: J. Benítez, ES - H. Vasen, NL MADRID 07/06/10

Scientific Programme

Genetic Testing for Hereditary Breast and Ovarian Cancer - BRCA1/2 ANALYSIS -

Understanding Hereditary Breast and Ovarian Cancer. Maritime Hereditary Cancer Service

MS: from disease management to patient management

Breast Health Program

INTERVENTIONS BREAST CANCER GENETICS YOUNG BREAST CANCER SURVIVORS

International Symposium on Malignant Pleural Mesothelioma

Scientific Committee Hilary Calvert UCL Cancer Institute, London, United Kingdom

ESO INSIDE TRACK CONFERENCE. 4 th FAMILIAL CANCER CONFERENCE. 7-8 June 2010 Madrid, Spain. Chair: J. Benítez, ES - H. Vasen, NL MADRID 07/06/10

ScreenWise. Breast, Cervical, and Hereditary Cancer Screenings OCTOBER 28, 2015

Advanced Video-Assisted and Thoracoscopic Procedures

BRCA Genes and Inherited Breast and Ovarian Cancer. Patient information leaflet

GENETIC CONSIDERATIONS IN CANCER TREATMENT AND SURVIVORSHIP

ONCOLOGY NURSING 7 TH ESO-EONS MASTERCLASS IN March 2014 Ermatingen (Lake Constance) Switzerland MASTERCLASS

STRESA 31/03/11 RARE SOLID CANCERS: AN INTRODUCTION. 31 March - 1 April 2011 Stresa, Italy. Chairs: P.G. Casali, IT - G. Gatta, IT

SUMMER SCHOOL organised by the Hepatology Committee of ESPGHAN

da Vinci Robotic Surgery Training Programs The Ohio State University Medical Center

29 January Rome, Italy

E UROPEAN C URRICULUM V ITAE F ORMAT

The Genetics of Early- Onset Breast Cancer. Cecelia Bellcross, Ph.D., M.S.,C.G.C. Department of Human Genetics Emory University School of Medicine

What s New in Rhinology 2012

ESO INSIDE TRACK CONFERENCE. 3 rd FAMILIAL CANCER CONFERENCE. 5-6 June 2008 Madrid, Spain MADRID. Chair: J.Benitez, ES - R. Eeles, UK - H.

January 12, Sincerely, Scott H. Kurtzman, MD, FACS Chair, NAPBC Standards and Accreditation Committee Attached (NAPBC Performance Report)

TEACH Summer School Cascais, Portugal 3-7 July, Training and Education for Advanced Clinicians and HCPs in Personalised Medicine

Cachexia and Nutrition in Advanced Cancer Patients: a Multidisciplinary Approach Chairs: M.S. Aapro, CH J. Herrstedt, DK F.

E UROPEAN PERSONAL INFORMATION

PROVIDER POLICIES & PROCEDURES

The CASP8 rs polymorphism and breast cancer risk in BRCA1 mutation carriers.

patient guide BRCA1 and BRCA2 Genetic Testing for Hereditary Breast and Ovarian Cancer

Research Methods for Respiratory Diseases

The Department of Vermont Health Access Medical Policy

Promises and challenges of developing new drugs in oncology

GRANT APPLICATION FORM: ORGANISING AN ESO EDUCATIONAL EVENT

Promises and challenges of developing new drugs in oncology

HEREDITARY BRCA1. Faulty gene INFORMATION LEAFLET. How Do I Reduce My Risk?

MEDICAL CHAMBERS T: + 44 (0) T: + 44 (0) F: + 44 (0) F: + 44 (0) E: info@108harleystreet.co.

First Invitation CONFERENCE August Real World Oncology. Emperors Palace, Kempton Park, South Africa

Ovarian Cancer Genetic Testing: Why, When, How?

Breast cancer and genetics

BRCA1 & BRCA2 GeneHealth UK

ELCC 2015 Industry Satellite Symposium The Treatment Roadmap for Squamous NSCLC. Thursday 16th April :10 14:20 Room C

The iq&a interactive Medical Intelligence Zone BRCA Gene Testing

Leah Jutzi MD, on behalf of OvCaRe

Oregon Survey Instrument

SKIN MELANOMA September 2006, Istanbul, TR

Breast Cancer. CSC Cancer Experience Registry Member, breast cancer

Training Requirements for the Specialty of Radiation Oncology

Magnetic Resonance Techniques in Neurodegenerative Diseases First Course Alzheimer s disease and frontotemporal lobar degeneration spectrum

Prevention GENEration. The Importance of Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome (HBOC)

Cancer Survivorship Care

This vision does not represent government policy but provides useful insight into how breast cancer services might develop over the next 5 years

From Concept to a Published Paper - a guide to excellence in Medical Research.

GENERAL QUESTIONS FOR YOUR DOCTOR OR NURSE. 3. Can you refer me to a breast cancer support group or counselor?

Best of San Antonio Breast Cancer Symposium

Hereditary Ovarian cancer: BRCA1 and BRCA2. Karen H. Lu MD September 22, 2013

LAPAROSCOPIC & ROBOTIC UROLOGY & PAEDIATRIC UROLOGY

ON CLINICAL PHARMACOLOGY OF ANTIRETROVIRALS 10 RESIDENTIAL COURSE January Starhotels Majestic. corso Vittorio Emanuele II 54 - TURIN

TENDON TRANSFERS IN RECONSTRUCTIVE TETRAPLEGIA HAND SURGERY

A European network on cervical cancer surveillance and control in the new Member States - AURORA

MEDICAL ONCOLOGY PROFILE

Hereditary Breast Cancer. Nicole Kounalakis, MD Assistant Professor of Surgery University of Colorado Medical Center

You re Invited About Us Distinctions Education Executive Education. Graduate Training Technology Contact Us

Breast Cancer s Link to Ovarian Cancer: It s in Your Genes. foundationforwomenscancer.org

13 May 14 May. SESSION 2.- Advances in hearing loss research II Chair: Andrew Forge

ICCBH ON CHILDREN S BONE HEALTH June 2015 SALZBURG, AUSTRIA. Announcement and Call for Abstracts

Healthcare Ethics Committees

We are pleased to welcome you to the IPRAS Course: Principles and techniques in Maxillofacial Trauma, Cancer & Aesthetics.

AOSpine Masters Symposium Adult deformity of the cervical, thoracic and lumbar spine

Hereditary Breast and Ovarian Cancer (HBOC)

REACHING OUT THROUGH THE WEB MILAN BREAST CANCER CONFERENCE Webcast and residential. 23/26 june 2015

British Thoracic Oncology Group (BTOG) Annual Report - April 2014 to March 2015

Date and place of birth 28th January 1958; Moretta (Cuneo) (Italy). Two children

The Eighth Annual Breast Cancer Symposium, 2015

International Tinbergen Institute Workshop 2013 Amsterdam, May 27 & 28, 2013

This document contains four General Surgery placement descriptions:

Genetic Counseling and Testing: Cancer Genetics

5 February Bari, Italy

WORKSHOP IN LUNG CANCER CLINICAL RESEARCH Improving opportunities in the LATAM region

ICD-10 Diagnostic Coding for. Breast Reconstruction

Call for proposals to host. the. ECSITE ANNUAL CONFERENCE 2018 or ECSITE ANNUAL CONFERENCE 2019

Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma

Magnetic Resonance Techniques in Multiple Sclerosis

Audit. Process for managing outliers in breast cancer surgery. March 2005

Transcription:

ESSO Course on the Management of High Risk Patients for Breast Cancer. A Multidisciplinary Approach 05-06 February 2016 BERLIN (DE)

ESSO Course on the Management of High Risk Patients for Breast Cancer. A Multidisciplinary Approach Chairs Tibor Kovacs, Guy s and St. Thomas Hospital, London, UK Isabel Teresa Rubio, Hospital Universitario Vall d Hebrón, Barcelona, SP Faculty members Antonis Antoniou, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK Andrew Baildam, Barts and The London Hospitals, Queen Mary, University of London, London, UK Serena Di Cosimo, Istituto Nazionale dei Tumori, Milan, IT Anju Kulkarni, Guy s and St. Thomas Hospital, London, UK Roel Mus, Radboud University Medical Center, Radboud, NL Sarah Pinder, King s College London, London, UK Marc Thill, Agaplesion Markus Hospital, Frankfurt, DE Lynda Wyld, Sheffield University, Sheffield, UK

Aim of the course This course will provide a comprehensive multidisciplinary approach to the theory and practice of the management of patients with increased risk for developing breast cancer. The goal will be to provide evidence based and up-to-date information on all aspects of care for those with a higher than average level of risk for developing breast cancer. The programme will address topics from basic science through risk assessment to complex clinical management and risk reduction strategies and will explore in depth the understanding of risk models, risk prediction, management of BRCA mutation positive, negative patients and those with contralateral breast cancer risk including surveillance, medical and surgical risk reduction strategies. The course will deliver a practical, workshop-based approach for surgeons and clinicians providing them with the scientific evidence and information to help their patients to reach informed decisions about their future. Educational Methods Clinical case discussions Plenary lectures Ideal course candidates Oncoplastic breast and plastic surgeons General surgery trainees with breast interest Specialist residents and trainees in breast surgery, surgical oncology Specialist breast surgeons with traditional training Gynecologists Course Coordination Ana Galán European Society of Surgical Oncology (ESSO) Email. ana.galan@essoweb.org

Course venue Arcotel John F Berlin Werderscher Markt 11, 10117 Berlin, Germany Accommodation For accommodation please contact the course coordinator Participation fee To ensure interactivity during the course, attendance is limited to 30 participants. The participation fee is 400 for ESSO members and 550 for non-esso members. It includes registration to the course, catering and a social dinner. Application Procedure To apply please go to the course webpage at www.essoweb.org Accreditation An application for accreditation has been submitted to the European Accreditation Council for CME (EACCME) of the European Union of Medical Specialists (UEMS)

Programme Friday 5 th February MOLECULAR BASES OF HEREDITARY BREAST CANCER 13:45-14:00 Welcome and introduction T. Kovacs, I. T. Rubio 14:00-14:30 BRCA and beyond - what else needs to be tested? A. Antoniou 14:30-15:00 Understanding risk models for breast cancer L. Wyld 15:00-16:00 Clinical cases discussion Who to test L. Wyld, A. Antoniou 16:00-16:15 Coffee break 16:15-16:45 Defining hight risk breast lesions and impact on breast cancer development S. Pinder 16:45-17:15 Surgical management of high risk lesions - LCIS, ADH, ALH, FEA I. T. Rubio 17:15-17:45 Imaging and follow up on high risk patients - LCIS, ADH, ALH, FEA R. Mus 19:30 Social dinner

Programme Saturday 6 th February HIGH RISK PATIENTS NO MUTATION CARRIERS/ BRCA NEGATIVE 08:00-08:30 Management of BRCA negative and non-tested patients demanding risk reduction strategies A. Kulkarni 08:30-09:30 Clinical cases S. Pinder, I. T. Rubio, R. Mus, A. Kulkarni 09:30-10:00 How to run a multidisciplinary BRCA clinic and MDT A. Baildam 10:00-10:15 Coffee break 10:15-10:45 Genetic testing at the surgical oncologist clinic I. T. Rubio 10:45-11:15 Risk reduction strategies for BRCA carriers. When is it time to start? A. Kulkarni 11:15-11:45 Long term surveillance of BRCA mutation carriers and patients with higher risk of developing, breast cancer R. Mus 11:45-12:45 Breast cancer risk reduction strategies: Medical Oncology- Chemoprevention S. Di Cosimo 12:45-13:15 Lunch BRCA MUTATION CARRIERS Surgical options-radical risk reduction strategies; the risk reduction mastectomy (NSM, SSM) T. Kovacs Options for immediate reconstruction A. Baildam 13:15-13:45 Risk of ovarian cancer and prophylactic surgery M. Thill 13:45-14:15 Mutation carriers with breast cancer: breast conservative surgery vs bilateral mastectomy T. Kovacs, I. T. Rubio

14:15-14:45 Breast cancer and fertility M. Thill 14:45-15:00 Coffee break 15:00-15:40 Clinical cases A. Baildam, S. Di Cosimo, T. Kovacs, M. Thill 15:40-16:40 Consensus Statement on Prophylactic Mastectomy

ESSO is grateful for the continuous support of its corporate sponsors European Society of Surgical Oncology (ESSO) Avenue E. Mounier 83 B 1200 Brussels Tel: +32 (0)2 5373106 Fax : +32 (0) 5390374 Email : info@essoweb.org Website : www.essoweb.org